Cointime

Kite Pharma

company

About

Kite Pharma is a development-stage biotechnology company designing and developing immune-based therapies to treat cancer indications.

Highlights

Stock Symbol
nasdaq:KITE
Total Funding Amount
$462.37M
Funding Rounds
6
Investors
4
Investments
12
Lead Investments
1

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$250.12M
Industries
Biotechnology,Health Care,Medical,Therapeutics
Founded date
Jan 1, 2009
Number Of Employee
101 - 250
Operating Status
Active
Stock Symbol
nasdaq:KITE
Legal Name
Kite Pharma, Inc.
Investor Type
Venture Capital

Kite Pharma is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies to treat different cancer indications. Kite has a portfolio of proprietary product candidates designed to stimulate the patient's own immune system to fight tumor cells. These potential therapies could provide novel strategies for the treatment and management of a wide range of tumor types.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
6
$462.37M
Kite Pharma has raised a total of $462.37M in funding over 2 rounds. Their latest funding was raised on Dec 10, 2015 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 10, 2015 Post-IPO Equity $250.12M — — — Detail
Jun 27, 2014 IPO $127M — — — Detail
May 2, 2014 Debt Financing $50M 1 — — Detail
May 15, 2013 Series A $20M 2 Alta Partners — Detail
Dec 20, 2012 Debt Financing $250K — — — Detail
Show More

Investments

Number of Investments
Number of Lead Investments
12
1
Kite Pharma has made 12 investments. Their most recent investment was on Dec 9, 2022, when Arcellx raised $100M.
Date Company Name
Round Money Raised Industry Lead Investor
Dec 9, 2022 Arcellx
Post-IPO Equity $100M Biopharma Yes
Jul 27, 2022 AlloVir
Post-IPO Equity $126.60M Biotechnology —
Nov 2, 2021 Shoreline Biosciences
Series B $140M Biotechnology —
Oct 12, 2021 EngFlow
Seed $3.70M Cloud Computing —
Feb 24, 2021 Orna Therapeutics
Series A $80M Biotechnology —
Show More

Investors

Number of Lead Investors
Number of Investors
1
4
Kite Pharma is funded by 4 investors. Alta Partners and Arie Belldegrun are the most recent investors.
Investor Name Lead Investor Funding Round
Alta Partners Yes Series A
Arie Belldegrun — Debt Financing
Two River — Series A
Riverbank Capital Securities — Series A

Employee Profiles

Number of Employee Profiles
17
Kite Pharma has 17 current employee profiles, including Employee John Rossi
John Rossi
Employee
Reggie Foster
Executive
Tamas Masztis
Executive
Lindsay Arnold
Employee
Joseph Wong
Executive
Show More

Exits

Kite Pharma has had 3 exits. Kite Pharma most notable exits include Arcellx ,   AlloVir

Date Company Name Exit Type Industry
Feb 4, 2022 Arcellx IPO Biopharma Detail
Jul 30, 2020 AlloVir IPO Biotechnology Detail
Dec 7, 2017 Cell Design Labs M&A Biotechnology Detail

Acquisition

Kite Pharma has acquired 1 organizations. Their most recent acquisition was Tmunity Therapeutics on Dec 20, 2022. They acquired Tmunity Therapeutics for 0.

Date Company Name
Industry Acquisition Type Price
Dec 20, 2022 Tmunity Therapeutics
Biotechnology acquisition — Detail
Cointime
Содержание
компания